Prasugrel

Drug Profile

Prasugrel

Alternative Names: CS-747; CS-747S; Effient; Efient; LY 640315; R-138727; R-99224

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company; Ube Industries
  • Developer Daiichi Sankyo Company; Eli Lilly; Ube Industries
  • Class Antiplatelets; Antithrombotics; Cyclopropanes; Fluorobenzenes; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Phase III Sickle cell anaemia; Stroke

Most Recent Events

  • 21 Oct 2016 Daiichi Sankyo completes a phase-III clinical trial in Stroke in Japan (PO) (JapicCTI-111582)
  • 25 May 2016 Single dose 20mg prasugrel available for Acute coronary syndromes with PCI in Japan
  • 20 Jan 2016 Japan's Pharmaceuticals and Medical Devices Agency approves 20mg single dose prasugrel for the treatment of Acute coronary syndrome with PCI in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top